Clinical trials: Fever
Yellow Fever Immunization
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
The purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and…
- Trial name
- NCT07103148
- Testing
- Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated
- Where
- 15 sites in Honduras, Mexico and 1 more
- Volunteers
- 2,440 people, healthy volunteers welcome
- Sponsor
- Sanofi
Familial Mediterranean Fever (FMF), Autoinflammation
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.
- Conditions
- Familial Mediterranean Fever (FMF), Autoinflammation, Periodic Fever, Fever
- Trial name
- NCT00001373
- Where
- 5 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Fever, Acute Pain
Using a Decision-making System to Support the Management of Fever and Acute Pain in Children
FEVER is a single-center, prospective, open-label, pre-market, pivotal, single-arm study aimed at demonstrating how the use of an algorithm integrated with a Class I Medical Device (Puntofarma®), which is made available through a…
- Trial name
- FEVER (NCT07344090)
- Testing
- Puntofarma® FEVER
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Qwince Innovation S.r.l.
Lassa Fever
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Lassa fever is an acute viral disease belonging to the category of viral hemorrhagic fevers. It is endemic in West Africa. Outbreaks occur every year, and it is estimated that between 100 000 and 300 000 individuals are infected…
- Trial name
- FIRST-IN-MOP (NCT07833436)
- Testing
- Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Ebola Virus Disease
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Trial name
- NCT03576690
- Testing
- REGN3470-3471-3479
- Sponsor
- Regeneron Pharmaceuticals
Rheumatic Fever, Rheumatic Heart Disease in Children
ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
The ACT4RHD trial is a multicentre, pragmatic, multi-arm, open-label adaptive platform trial addressing multiple therapeutic questions in patients with ARF and carditis.
- Conditions
- Rheumatic Fever, Rheumatic Heart Disease in Children, Acute Rheumatic Fever, Rheumatic Heart Disease
- Trial name
- ACT4RHD (NCT07830108)
- Testing
- Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 600 people
- Sponsor
- Starship Child Health, Te Toka Tumai Auckland
Rift Valley Fever, Hemorrhagic Fevers, Viral
RVF and Other Emerging Infectious Diseases in East and Central Africa
Rift Valley fever (RVF), a disease transmitted from livestock (cattle, sheep, goats, camels) to humans more commonly occurs in the East and Central Africa (ECA) regions where more than 15 major epidemics affecting more than one…
- Trial name
- NCT05139524
- Testing
- Evidence of past or recent RVF exposure
- Where
- 10 sites in Democratic Republic of the Congo, Kenya and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Washington State University
Pyrexia
Comparison of FDG-PET/CT and CECT-CAP as Upfront Imaging Modality for the Diagnosis of Pyrexia of Unknown Origin
Pyrexia of unknown origin (PUO) remains one of the most challenging diagnostic problems in modern medicine. Despite advances in laboratory diagnostics, microbiological techniques, imaging modalities, and molecular testing, a…
- Trial name
- CET-PET-PUO (NCT07816783)
- Testing
- FDG-PET, CECT, Standard care of therapy
- Where
- India
- Volunteers
- 132 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Familial Mediterranean Fever
Genotype and Phenotype in Pediatric Familial Mediterranean Fever
This cross-sectional study aims to assess the spectrum of MEFV gene mutations and their relation to clinical manifestations and disease severity in children with Familial Mediterranean Fever attending Assiut University Children…
- Trial name
- NCT07849998
- Volunteers
- 84 people
- Sponsor
- Assiut University
Neutropenic Fever, Acute Lymphoblastic Leukemia
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
The goal of this clinical trial is To evaluate the benefit of levofloxacin prophylaxis in prolonging the median time to first febrile neutropenia in pediatric ALL patients during induction phase.
- Trial name
- NCT07320534
- Testing
- Levofloxacin
- Where
- Indonesia
- Volunteers
- 49 people
- Sponsor
- Gadjah Mada University
Chikungunya Virus
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.
- Trial name
- NCT07003984
- Testing
- CHIKV VLP vaccine
- Where
- 15 sites in United States, Philippines and 1 more
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Healthy Adult, Healthy Adolescents
Evaluation of IXCHIQ® Vaccine Immunogenicity
The goal of this clinical trial is to evaluate the quality and duration of the immune response against chikungunya virus elicited by the IXCHIQ® vaccine in healthy adults and adolescents.
- Trial name
- IMUNO-CHIQ (NCT07846293)
- Testing
- IXCHIQ vaccine
- Where
- Brazil
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mauro Martins Teixeira
Sepsis, Infections
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
A pre/post interventional use trial, with ED patients who are initially triaged to locations other than a dedicated patient room in the main ED (e.g., waiting room, hallway bed, and/or the staging area/fast track area) with…
- Conditions
- Sepsis, Infections, Tachycardia, Fever
- Trial name
- TIMED (NCT06637904)
- Testing
- TriVerity Test
- Where
- 2 sites in United States
- Volunteers
- 320 people
- Sponsor
- Inflammatix
Chikungunya Virus Infection
Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana
In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and…
- Trial name
- CHIK-RE-VAC (NCT06928753)
- Testing
- IXCHIQ, VIMKUNYA
- Where
- 2 sites in French Guiana, Reunion
- Volunteers
- 1,505 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Lassa Fever
DMID 23-0015; Lassa Fever CVD 1000
This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen.
- Trial name
- NCT06546709
- Testing
- LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, LASSARAB+ aPHAD-SEat 1400rU
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wilbur Chen, MD, MS
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06579755
- Testing
- TDV
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Takeda
Coccidioidomycosis, Disseminated Fungal Infection
A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care
The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated…
- Conditions
- Coccidioidomycosis, Disseminated Fungal Infection, Coccidioides Infection, Coccidioides Immitis Infection
- Trial name
- COCCIMETRICS (NCT07712484)
- Testing
- Olorofim
- Volunteers
- 50 people
- Sponsor
- F2G Ltd
Familial Mediterranean Fever (FMF ), Metabolic Syndrome
Metabolic Syndrome Resposne to Dietary Limitations in Familial Mediterranean Fever in Adolescents
metabolic syndrome may be prevalent in familial Mediterrean fever. Dietary limitations are main treatment in metabilc syndrome
- Trial name
- NCT07833007
- Testing
- low calorie diet
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Septic Shock
Fever Control Using External Cooling in Mechanically Ventilated Patients With Septic Shock
The best strategy for managing fever in patients with septic shock remains unknown. In a pilot study, the investigators showed that fever control at normothermia allowed a better control of shock and evolution of organ failures.
- Trial name
- NCT04494074
- Testing
- External Cooling
- Where
- 33 sites in France
- Volunteers
- 820 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil